Up-to-date treatment and management of myositis.

Abstract

PURPOSE OF REVIEW:

Myositis, or idiopathic inflammatory myopathy, is an overarching concept that includes dermatomyositis, polymyositis, immune-mediated necrotizing myopathy and the antisynthetase syndrome. Glucocorticoids are still considered the mainstay of treatment of myositis but some patients require add-on immunosuppressive therapy because of insufficient response to glucocorticoids, relapses when glucocorticoids are tapered, or because they incur glucocorticoid-related side effects.

RECENT FINDINGS:

The goal of this article was to review (PubMed search from January 2019 through June 2020) the efficacy and safety of standard and novel agents used in adult dermatomyositis, polymyositis, immune-mediated necrotizing myopathy and the antisynthetase syndrome.

SUMMARY:

Established therapies beyond glucocorticoids continue to have a major role in managing patients with myositis. In addition, novel agents are being tried for refractory manifestations of myositis.

• Authors: Nicolò Pipitone, Carlo Salvarani
• Journal: Current opinion in rheumatology (Curr Opin Rheumatol) Vol. 32 Issue 6 Pg. 523-527 (11 2020) ISSN: 1531-6963 [Electronic] United States
• PMID: 32890030 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents
• Biological Products
• Glucocorticoids

Topics

• Anti-Inflammatory Agents (therapeutic use)
• Biological Products (therapeutic use)
• Dermatomyositis (drug therapy)
• Disease Management
• Glucocorticoids (therapeutic use)
• Humans
• Myositis (drug therapy)
• Polymyositis (drug therapy)
• Treatment Outcome